Sympathikusaktivität bei Niereninsuffizienz – Therapieoptionen

Zusammenfassung

Patienten mit chronischer Niereninsuffizienz zeigen eine tonisch erhöhte sympathische Nervenaktivität, die zu ihrem deutlich erhöhten kardiovaskulären Risiko beiträgt. Ursache ist die Aktivierung renaler sympathischer Afferenzen in den erkrankten Nieren. Therapeutisch kommen für hypertensive chronisch nierenkranke Patienten in erster Linie Hemmstoffe des Renin-Angiotensin-Systems und zentrale Sympathikolytika in Frage. Die Rolle der katheterbasierten renale Denervierung wird aktuell bei diesem Patientenkollektiv überprüft.

Abstract

Patients with chronic renal failure are characterized by a tonic elevation of sympathetic tone. This factor largely contributes to their increased cardiovascular risk. The increased sympathetic drive is caused by activiation of renal afferent fibers in the diseased kidneys. Therapeutic options for hypertensive patients with chronic renal failure with respect to their sympathetic overactivity are inhibitors of the renin-angiotensin-system and central sympatholytic drugs. The role of catheter-based renal denervation in these patients is currently under investigation.

Schlüsselwörter

sympathische Nervenaktivität - Niereninsuffizienz - renale Denervierung - RAS-Hemmstoffe

Keywords

sympathetic nerve activity - chronic renal failure - renal denervation - RAS-blockade

• Literatur

• 1 Amann K, Rump LC, Simonaviciene A et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11: 1469-1478
• 2 Barenbrock M, Kosch M, Joster E et al. Reduced arterial distensibility is a predictor of cardiovascular disease in patients after renal transplantation. J Hypertens 2002; 20: 79-84
• 3 Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25: 878-882
• 4 Converse Jr RL, Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-1918
• 5 Costa F, Diedrich A, Johnson B et al. Adenosine, a metabolic trigger of the exercise pressor reflex in humans. Hypertension 2001; 37: 917-922
• 6 Curtis JJ, Luke RG, Dustan HP et al. Remission of essential hypertension after renal transplantation. N Engl J Med 1983; 309: 1009-1015
• 7 Di Daniele N, De Francesco M, Violo L et al. Renal sympathetic nerve ablation for the treatment of difficult-to-control or refractory hypertension in a haemodialysis patient. Nephrol Dial Transplant 2012; 27: 1689-1690
• 8 DiBona GF, Jones SY, Kopp UC. Renal mechanoreceptor dysfunction: an intermediate phenotype in spontaneously hypertensive rats. Hypertension 1999; 33: 472-475
• 9 Hausberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-1979
• 10 Hausberg M, Tokmak F, Pavenstadt H et al. Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease. J Hypertens 2010; 28: 1920-1927
• 11 Hering D, Mahfoud F, Walton AS et al. Renal denervation in moderate to severe CKD. J Amer Soc Nephrol 2012; 23: 1250-1257
• 12 Kiuchi MG, Maia GL, de Queiroz Carreira MA et al. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Eur Heart J 2013; 34: 2114-2121
• 13 Klein IH, Ligtenberg G, Oey PL et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12: 2427-2433
• 14 Klein IH, Ligtenberg G, Oey PL et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14: 425-430
• 15 Kosch M, Barenbrock M, Kisters K et al. Relationship between muscle sympathetic nerve activity and large artery mechanical vessel wall properties in renal transplant patients. J Hypertens 2002; 20: 501-508
• 16 Ligtenberg G, Blankestijn PJ, Oey PL et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-1328
• 17 Mallamaci F, Tripepi G, Maas R et al. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol 2004; 15: 435-441
• 18 Midtvedt K, Hartmann A, Bentdal O et al. Bilateral nephrectomy simultaneously with renal allografting does not alleviate hypertension 3 months following living-donor transplantation. Nephrol Dial Transplant 1996; 11: 2045-2049
• 19 Neumann J, Ligtenberg G, Oey L et al. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004; 15: 2902-2907
• 20 Ott C, Schmid A, Ditting T et al. Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research. J Clin Hypertens 2012; 14: 799-801
• 21 Penne EL, Neumann J, Klein IH et al. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol 2009; 22: 208-215
• 22 Recordati G, Moss NG, Genovesi S et al. Renal chemoreceptors. J Auton Nerv Syst 1981; 3: 237-251
• 23 Schlaich MP, Bart B, Hering D et al. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol 2013; Feb 28. pii: S0167-5273(13)00278-7
• 24 Schlaich MP, Sobotka P, Krum H et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-934
• 25 Schlaich MP, Socratous F, Hennebry S et al. Sympathetic activation in chronic renal failure. J Amer Soc Nephrol 2009; 20: 933-939
• 26 Schwenger V, Zeier M, Ritz E. Hypertension after renal transplantation. Curr Hypertens Rep 2001; 3: 434-439
• 27 Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc 1953; 152: 1501-1504
• 28 Teixeira MC, Nahas WC, Mazucchi E et al. Role of the peripheral renin profile in predicting blood pressure control after bilateral nephrectomy in renal-transplanted patients. Nephrol Dial Transplant 1998; 13: 2092-2097
• 29 Vonend O, Marsalek P, Russ H et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003; 21: 1709-1717
• 30 Ye S, Gamburd M, Mozayeni P et al. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998; 11: 723-728
• 31 Ye S, Nosrati S, Campese VM. Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure (CRF). J Clin Invest 1997; 99: 540-548
• 32 Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-1359